hepatobiliary malignant tumor
Conditions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old male and female; 2. Hepatobiliary malignancy has undergone resection; 3. Histopathology or cytology confirmed as primary liver cancer or gallbladder malignancy; 4. No serious underlying diseases; 5. Have not previously treated with radiotherapy and chemotherapy; 6. No significant heart, lung, kidney dysfunction, no HIV or syphilis infection; 7. All patients should be signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Preoperative general poor, it is estimated can not tolerate surgery and postoperative chemotherapy and targeted therapy; 2.Combined with metastasis; unstable angina, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, QT prolongation (> 450ms); 3. Other parts of malignant tumors emerged within the last 5 years; 4. Patients can not accept follow-up or are participating in other clinical trials; 5. The presence of drug abuse; or any medical, psychological or social condition that may affect research, instability of patient compliance, or even endanger the safety of the patient; 6. Conduct other experimental medications outside this study within 4 weeks prior to the study's initiation; or concurrently participate in another clinical study that may have an impact on the results of this study; 7. Mental or medical instability makes patients unwilling or unwilling to sign an informed consent form; 8. After comprehensive assessment, the researchers think that is not suitable for patients involved in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Progressive survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate;Disease continue to reaction time;Five-year survival rate;Quality of life score; | — |
Countries
China
Contacts
Peking Union Medical College Hospital